Fundraising Fox

Arima Genomics

Founded 2015 · 43 employees on LinkedIn · 2 known investors

Arima Genomics develops DNA-based cancer diagnostics that combine genomic sequence with 3D genome structural information (via Hi-C sequencing) to detect fusions, rearrangements, ecDNA, and other structural drivers of cancer. It serves clinicians and biopharma partners through its Aventa clinical testing brand and translational science collaborations, using routine FFPE tumor samples to guide diagnosis and therapy selection.

BiotechHealthtechMedical Devices

Founders & leadership

Arima Genomics was founded in 2015 by Sid Selvaraj.

SSSid Selvaraj
Sid SelvarajFounder & Chief Operating Officer
TWTom Willis
Tom WillisChief Executive Officer
ASAnthony Schmitt
Anthony SchmittSenior Vice President, Science
EDErin Davis
Erin DavisVice President, Marketing

Investors · 2

Berkeley CatalystBerkeley
Illumina VenturesFoster City

Competitors · 3

by search overlap
IDbyDNA56 shared keywordsScalable, high throughput DNA sequencing platforms.
Oup48 shared keywordsOxford University Press publishes research, educational, and reference materials, including reports on reading and children's learning, and reference resources such as its dictionary "Word of the Day." It serves readers, educators, and learners across a wide range of subjects worldwide.
Active Motif23 shared keywords

Companies competing with Arima Genomics for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 10 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase II2023$2.1M
National Institutes of Health (NIH)National Institutes of HealthPhase II2023$1M
National Institutes of Health (NIH)National Institutes of HealthPhase II2021$2.1M
National Institutes of Health (NIH)National Institutes of HealthPhase II2021$2.1M
National Institutes of Health (NIH)National Institutes of HealthPhase II2020$2M
National Institutes of Health (NIH)National Institutes of HealthPhase II2018$1.7M
National Institutes of Health (NIH)National Institutes of HealthPhase II2017$1.8M
National Institutes of Health (NIH)National Institutes of HealthPhase I2016$290.6K
National Institutes of Health (NIH)National Institutes of HealthPhase I2016$274.1K
National Institutes of Health (NIH)National Institutes of HealthPhase ISTTR2015$729.7K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does Arima Genomics do?
Arima Genomics develops DNA-based cancer diagnostics that combine genomic sequence with 3D genome structural information (via Hi-C sequencing) to detect fusions, rearrangements, ecDNA, and other structural drivers of cancer. It serves clinicians and biopharma partners through its Aventa clinical testing brand and translational science collaborations, using routine FFPE tumor samples to guide diagnosis and therapy selection.
Who founded Arima Genomics?
Arima Genomics was founded by Sid Selvaraj in 2015.
Who are Arima Genomics's investors?
Arima Genomics's investors include Berkeley Catalyst, Illumina Ventures.